Abstract
In this issue of Blood, the articles by Shaham et al and Wang et al are the first to identify microRNA 486 (miR-486) as a requisite oncomiR and credible therapeutic target in myeloid leukemia of Down syndrome (ML-DS) and chronic myeloid leukemia (CML) by showing that these 2 leukemias co-opt miR-486 functions in normal erythroid progenitor progrowth and survival activity.
MeSH terms
-
Animals
-
Cell Proliferation / genetics*
-
Down Syndrome / genetics*
-
Drug Resistance, Neoplasm / genetics*
-
Erythropoiesis / genetics*
-
Humans
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
-
Leukemia, Myeloid, Acute / genetics*
-
Megakaryocyte-Erythroid Progenitor Cells / physiology*
-
MicroRNAs / physiology*
Substances
-
MIRN486 microRNA, human
-
MicroRNAs